NIFEDIPINE CAPSULE

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

NIFEDIPINE

Saadav alates:

AA PHARMA INC

ATC kood:

C08CA05

INN (Rahvusvaheline Nimetus):

NIFEDIPINE

Annus:

5MG

Ravimvorm:

CAPSULE

Koostis:

NIFEDIPINE 5MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

DIHYDROPYRIDINES

Toote kokkuvõte:

Active ingredient group (AIG) number: 0115253003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2010-06-14

Toote omadused

_NIFEDIPINE (Nifedipine Capsules) _
_Page 1 of 36_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NIFEDIPINE
Nifedipine Capsules
Capsules, 5 mg and 10 mg, Oral
USP
Anti-Anginal Agent
AA PHARMA INC.
1165 Creditstone Road Unit # 1
Vaughan, Ontario
L4K 4N7
www.aapharma.ca/en/
Date of Initial Authorization:
JUN 16, 2010
Date of Revision:
DEC 01, 2023
Submission Control Number: 271662
_NIFEDIPINE (Nifedipine Capsules) _
_Page 2 of 36_
RECENT MAJOR LABEL CHANGES
None
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.4
Administration
.........................................................................................................
5
4.5
Missed Dose
...............................................................................